Loading...
•
Jun 30, 2021
Celsion Q2 2021 Earnings Report
Celsion reported a net loss of $5.4 million, expanded its Vaccine Advisory Board, and strengthened its balance sheet through registered direct offerings.
Key Takeaways
Celsion Corporation announced its second quarter 2021 financial results, reporting a net loss of $5.4 million, or $0.06 per share. The company highlighted encouraging resection results from the Phase II OVATION 2 Study and the expansion of its Vaccine Advisory Board. Celsion ended the quarter with $64.5 million in cash and believes it has sufficient capital to fund operations through 2024.
GEN-1 continues to show encouraging resection results at the 100 mg/m² dose cohort in the Phase II OVATION 2 Study.
The Data Safety Monitoring Board (DSMB) unanimously recommended that the OVATION 2 Study continue treating patients with the 100 mg/m2 dose.
Celsion strengthened its capabilities in vaccine development with the expansion of its Vaccine Advisory Board.
Celsion GmbH was established to manage investigator-sponsored development of ThermoDox®.